Discontinued — last reported Q4 '24
Operating
Net gains (losses) on investments
Year-over-year, this metric grew by 100.0%, from -$956.00K to $0.00. Over 2 years (FY 2023 to FY 2025), Net gains (losses) on investments shows an upward trend with a -63.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2018
Last reportedQ4 2024
How to read this metric
Positive values indicate successful investment management, while negative values reflect market volatility or poor asset performance.
Detailed definition
This captures the non-cash gains or losses realized from the sale or revaluation of equity investments and securities. I...
Peer comparison
Common for large corporations with diversified portfolios or strategic minority stakes.
Metric ID:
gain_loss_on_investmentsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$4.43M | $18.69M | -$31.16M | -$1.10M | -$7.85M | -$2.27M | $1.40M | -$16.84M | $0.00 | $78.00K | -$1.37M | -$1.57M | -$166.00K | -$956.00K | -$1.35M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +521.5% | -266.7% | +96.5% | -615.6% | +71.1% | +161.8% | <-999% | +100.0% | — | <-999% | -14.6% | +89.4% | -475.9% | -41.2% | +100.0% | — | — |
| YoY Change | — | — | — | +75.3% | -142.0% | +92.7% | +227.6% | -114.6% | — | +103.4% | -197.6% | +90.7% | — | <-999% | +1.2% | +100.0% | +100.0% | +100.0% |
Range-$31.16M – $18.69M
CAGR-100.0%
Avg YoY Growth-68.4%
Median YoY Growth+90.7%
Current Streak3 quarters growth
Net gains (losses) on investments at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's net gains (losses) on investments?
- Alnylam Pharmaceuticals (ALNY) reported net gains (losses) on investments of $0.00 in Q1 2026.
- How has Alnylam Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- Alnylam Pharmaceuticals's net gains (losses) on investments increased by 100.0% year-over-year, from -$956.00K to $0.00.
- What is the long-term trend for Alnylam Pharmaceuticals's net gains (losses) on investments?
- Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's net gains (losses) on investments has grown at a -63.9% compound annual growth rate (CAGR), from -$17.71M to -$2.31M.
- What does net gains (losses) on investments mean?
- The profit or loss made from selling or holding financial investments.